Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid®1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States. The companies have launched four other strengths of the product in March 2022 in the US market.

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations.

Teva to Present at the Barclays Global Healthcare Conference

Teva Pharmaceutical has seen sequential years of revenue declines since its Allergan deal nearly eight years ago. Leverage seems under control, certainly if results can really start to stabilize, or even grow.

Teva Pharmaceutical: Stagnation To Finally End?

Viatris

Teva is the world's largest maker of generic drugs. Viatris offers an above-average dividend yield.

Better Generics Pharmaceutical Stock: Teva or Viatris?

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,490,000,000 (equivalent) of its sustainability-linked senior notes (the “Notes”).

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000 (the “Total Maximum Amount”) of the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 7.

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

TEL AVIV--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,060,000,000 (equivalent) of sustainability-linked senior notes. The notes offering reflects Teva's continued strong commitment to sustainable finance to help address some of the greatest challenges of our time.

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas.

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients' Lives

Energy Transfer LP Unit

Fresenius Medical Care

Organon & Co

Taro Pharmaceutical Industries

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). AUSTEDO XR is an additional formulation of the currently marketed twice-daily AUSTEDO.

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets

AbbVie

Alvotech SA

Amgen

Bristol-Myers

Coherus BioSciences

Cigna

CVS Health

GlaxoSmithKline

Johnson & Johnson

Merck

Novo Nordisk

Novartis

Pfizer

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

It's among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie.

Competition Coming For AbbVie's Blockbuster Humira

Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even though Copaxone sales declined.

What To Expect From Teva Pharmaceutical In 2023 With A New CEO

Kinder Morgan

Owens-Illinois

TransDigm

AMERCO

David Abrams (Trades, Portfolio), founder of Abrams Capital Management, disclosed in a regulatory portfolio update filing that his firm's top trades during the fourth quarter included the transfer of its U-Haul Holding Co. ( UHAL , Financial)( UHAL.B , Financial) holding from voting shares to non-voting shares. The firm also boosted its position in Meta Platforms Inc. ( META , Financial), exited its positions in O-I Glass Inc. ( OI , Financial) and Kinder Morgan Inc. ( KMI , Financial) and trimmed its holdings in TransDigm Group ( TDG , Financial) and Teva Pharmaceutical Industries ( TEVA , Financial).

Top Trades of David Abrams' Firm in the 4th Quarter

Axsome Therapeutics

Teva Pharmaceutical said Monday it plans to make a knockoff of Axsome Therapeutics' new depression treatment, leading AXSM stock to tumble. The post Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling appeared first on Investor's Business Daily.

Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling

TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.

TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Florida to settle the state's price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $6.73 million, and the state will dismiss all of its claims against Teva and its affiliates once payment has been made.

Teva Reaches Agreement With Florida to Settle the State's Price Fixing Claims

Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q4 2022 Earnings Conference Call February 8, 2023 8:00 AM ET Company Participants Ran Meir - Senior Vice President, Head of Investor Relations Richard Francis - Chief Executive Officer Eli Kalif - Executive Vice President and Chief Financial Officer Sven Dethlefs - Executive Vice President, North America Commercial Conference Call Participants Umer Raffat - Evercore ISI Gary Nachman - BMO Capital Markets Glen Santangelo - Jefferies Jason Gerberry - Bank of America Balaji Prasad - Barclays Elliot Wilbur - Raymond James Christopher Schott - JPMorgan Rishi Parekh - JPMorgan Operator Welcome to the Teva's Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] Please be advised that this conference is being recorded.

Teva Pharmaceutical Industries Limited (TEVA) Q4 2022 Earnings Call Transcript

Investors were disappointed with the drugmaker's 2023 outlook.

Why Teva Pharmaceutical Stock Is Sliding Today

Teva Pharmaceutical missed fourth-quarter expectations Wednesday and issued light guidance for 2023. Teva stock toppled.

Teva Pharmaceutical Stock Dives On Fourth-Quarter Miss, Light 2023 Guidance

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022. Q4 and FY 2022 highlights:   Q4 2022 FY 2022 Revenues   $3.9 billion   $14.9 billion GAAP diluted loss per share   $(1.10)   $(2.12) Non-GAAP diluted EPS   $0.71   $2.

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Lovesac Company

Walgreens

These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.

Nasdaq Bear Market: 3 Tantalizing Value Stocks That Can Double Your Money by 2026

Catalyst Pharmaceuticals

iShares Nasdaq Biotechnology ETF

Inspire Medical Systems Inc

Novocure

Revance Therapeutics

Vertex Pharmaceuticals

Zai Lab Ltd.

Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.

Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

News for Teva Pharmaceutical Stock (TEVA)